UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a “turnaround” is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or is it too early to call the turnaround complete?
Bull case
One of the most prominent factors supporting Medtronic’s (NYSE:MDT) turnaround story is the company’s reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. The trends suggest that the company is exhibiting continued operational rigor and building momentum in its highest growth opportunities, including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS.
Furthermore, Medtronic’s (NYSE:MDT) cardiac segment is emerging as one of the most prominent growth drivers for the company, as the Cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth. Several of the company’s newer product launches are beginning to contribute meaningfully to growth, helping strengthen its competitive position in several high-growth markets. It is also heavily investing in innovation and M&A, along with targeted investments in high-growth segments such as ICE catheter technology.
Another positive sign for investors is the considerable progress Medtronic (NYSE:MDT) has made in its high-growth platforms, including Symplicity Spyral for hypertension, now annualizing at $100 million. The company may also benefit from improving sentiment across the broader MedTech sector. BTIG recently noted in its research note previewing Q2 results in the sector that MedTech appears to be stabilizing following a period of underperformance. The firm believes that this stabilization is consistent with the overall market breadth expansion and broader momentum unwinding away from Semis/AI. While earnings cannot be considered a cure-all, they could serve as a catalyst for sentiment improvement, according to BTIG. This holds especially true if the sector can exhibit relative utilization strength and execution in a dynamic macro-environment.
Bear Case
However, investors may want to wait for several more quarters of consistent execution before concluding that Medtronic’s (NYSE:MDT) turnaround is complete. Management has spent several years attempting to accelerate growth, and the company’s recent momentum still needs to prove sustainable across multiple quarters.
It is also significant to note that much of Medtronic’s recent momentum has been concentrated in a handful of high-growth product categories, which raises the question of whether growth can become more broad-based across the company’s portfolio. This concern is further amplified as competition remains intense in cardiovascular devices and robotic surgery, especially from peers like Intuitive Surgical and Boston Scientific.
Tariffs are another important factor for investors to monitor. Management stated that they affected Medtronic’s (NYSE:MDT) business by $74 million, representing an 80 basis points headwind. They are anticipated to continue affecting gross margins, with fiscal year 2027 embedding an impact of around $250 million with no assumed refunds.
Structural Heart remains another area investors will likely watch closely. Management described the U.S. market as “softer” during the quarter and partly attributed the weakness to low-risk data trends. Medtronic (NYSE:MDT) is also uncertain about the MiniMed separation timing and guided conservatively by including a full year of diabetes in FY 2027. However, if the company separates before the end date, it could see potential upside from its current guidance.
Medtronic (NYSE:MDT) expects fiscal year 27 to see an organic revenue growth of 6.75% to 7.25%, including approximately 11.5% to 12% organic growth in Q1. Whether the company’s turnaround story gains broader investor acceptance will likely depend on its ability to sustain growth across its high-growth businesses while delivering consistent execution throughout fiscal 2027.
While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
